145 related articles for article (PubMed ID: 21997170)
1. Surgical risk score predicts suboptimal debulking or a major perioperative complication in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Stashwick C; Post MD; Arruda JS; Spillman MA; Behbakht K; Davidson SA; Kelly MG
Int J Gynecol Cancer; 2011 Nov; 21(8):1422-7. PubMed ID: 21997170
[TBL] [Abstract][Full Text] [Related]
2. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer.
Suidan RS; Ramirez PT; Sarasohn DM; Teitcher JB; Mironov S; Iyer RB; Zhou Q; Iasonos A; Paul H; Hosaka M; Aghajanian CA; Leitao MM; Gardner GJ; Abu-Rustum NR; Sonoda Y; Levine DA; Hricak H; Chi DS
Gynecol Oncol; 2014 Sep; 134(3):455-61. PubMed ID: 25019568
[TBL] [Abstract][Full Text] [Related]
3. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602.
Onda T; Satoh T; Saito T; Kasamatsu T; Nakanishi T; Nakamura K; Wakabayashi M; Takehara K; Saito M; Ushijima K; Kobayashi H; Kawana K; Yokota H; Takano M; Takeshima N; Watanabe Y; Yaegashi N; Konishi I; Kamura T; Yoshikawa H;
Eur J Cancer; 2016 Sep; 64():22-31. PubMed ID: 27323348
[TBL] [Abstract][Full Text] [Related]
4. Poor Prognostic Factors in Patients Undergoing Surgery After Neoadjuvant Chemotherapy for Ovarian, Tubal, or Peritoneal Cancer.
Kaban A; Topuz S; Saip P; Sozen H; Celebi K; Salihoglu Y
J Obstet Gynaecol Can; 2017 Dec; 39(12):1163-1170. PubMed ID: 28784563
[TBL] [Abstract][Full Text] [Related]
5. Use of ablation and ultrasonic aspiration at primary debulking surgery in advanced stage ovarian, fallopian tube, and primary peritoneal cancer.
Li S; Manning-Geist B; Gockley A; Ramos A; Sisodia RC; Del Carmen M; Growdon WB; Horowitz N; Berkowitz R; Worley M
Int J Gynecol Cancer; 2020 Jul; 30(7):1052-1057. PubMed ID: 32487686
[TBL] [Abstract][Full Text] [Related]
6. Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience.
Fagotti A; Vizzielli G; Fanfani F; Costantini B; Ferrandina G; Gallotta V; Gueli Alletti S; Tortorella L; Scambia G
Gynecol Oncol; 2013 Nov; 131(2):341-6. PubMed ID: 23938372
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of a risk-calculator for adverse perioperative outcomes for women with ovarian cancer.
Cham S; Chen L; St Clair CM; Hou JY; Tergas AI; Melamed A; Ananth CV; Neugut AI; Hershman DL; Wright JD
Am J Obstet Gynecol; 2019 Jun; 220(6):571.e1-571.e8. PubMed ID: 30771346
[TBL] [Abstract][Full Text] [Related]
8. Moving beyond "complete surgical resection" and "optimal": Is low-volume residual disease another option for primary debulking surgery?
Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
Gynecol Oncol; 2018 Aug; 150(2):233-238. PubMed ID: 29933927
[TBL] [Abstract][Full Text] [Related]
9. Recurrence patterns of advanced ovarian, fallopian tube, and peritoneal cancers after complete cytoreduction during interval debulking surgery.
Usami T; Kato K; Taniguchi T; Abe A; Nomura H; Yamamoto A; Matoda M; Okamoto S; Kondo E; Omatsu K; Kawamata Y; Takeshima N
Int J Gynecol Cancer; 2014 Jul; 24(6):991-6. PubMed ID: 24905612
[TBL] [Abstract][Full Text] [Related]
10. Management of epithelial cancer of the ovary, fallopian tube, and primary peritoneum. Long text of the Joint French Clinical Practice Guidelines issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and endorsed by INCa. Part 1: Diagnostic exploration and staging, surgery, perioperative care, and pathology.
Lavoue V; Huchon C; Akladios C; Alfonsi P; Bakrin N; Ballester M; Bendifallah S; Bolze PA; Bonnet F; Bourgin C; Chabbert-Buffet N; Collinet P; Courbiere B; De la Motte Rouge T; Devouassoux-Shisheboran M; Falandry C; Ferron G; Fournier L; Gladieff L; Golfier F; Gouy S; Guyon F; Lambaudie E; Leary A; Lecuru F; Lefrere-Belda MA; Leblanc E; Lemoine A; Narducci F; Ouldamer L; Pautier P; Planchamp F; Pouget N; Ray-Coquard I; Rousset-Jablonski C; Senechal-Davin C; Touboul C; Thomassin-Naggara I; Uzan C; You B; Daraï E
J Gynecol Obstet Hum Reprod; 2019 Jun; 48(6):369-378. PubMed ID: 30936027
[TBL] [Abstract][Full Text] [Related]
11. Perioperative epidural use and survival outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer.
Tseng JH; Cowan RA; Afonso AM; Zhou Q; Iasonos A; Ali N; Thompson E; Sonoda Y; O'Cearbhaill RE; Chi DS; Abu-Rustum NR; Long Roche K
Gynecol Oncol; 2018 Nov; 151(2):287-293. PubMed ID: 30185381
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer.
Suidan RS; Leitao MM; Zivanovic O; Gardner GJ; Long Roche KC; Sonoda Y; Levine DA; Jewell EL; Brown CL; Abu-Rustum NR; Charlson ME; Chi DS
Gynecol Oncol; 2015 Aug; 138(2):246-51. PubMed ID: 26037900
[TBL] [Abstract][Full Text] [Related]
13. Stage III disease of ovarian, tubal and peritoneal cancers can be accurately diagnosed with pre-operative CT. Japan Clinical Oncology Group Study JCOG0602.
Onda T; Tanaka YO; Kitai S; Manabe T; Ishikawa M; Hasumi Y; Miyamoto K; Ogawa G; Satoh T; Saito T; Kasamatsu T; Nakanishi T;
Jpn J Clin Oncol; 2021 Feb; 51(2):205-212. PubMed ID: 33556170
[TBL] [Abstract][Full Text] [Related]
14. Diverting ileostomy during primary debulking surgery for ovarian cancer: Associated factors and postoperative outcomes.
Tseng JH; Suidan RS; Zivanovic O; Gardner GJ; Sonoda Y; Levine DA; Abu-Rustum NR; Tew WP; Chi DS; Long Roche K
Gynecol Oncol; 2016 Aug; 142(2):217-24. PubMed ID: 27261325
[TBL] [Abstract][Full Text] [Related]
15. Is minimal invasive surgery for primary and secondary debulking of ovarian/peritoneal/fallopian tube cancer going too far?
Gorostidi M
Int J Gynecol Cancer; 2014 Sep; 24(7):1138-9. PubMed ID: 25054450
[No Abstract] [Full Text] [Related]
16. Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less.
Chi DS; Ramirez PT; Teitcher JB; Mironov S; Sarasohn DM; Iyer RB; Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Brown CL; Aghajanian C; Gershenson DM; Hoskins WJ; Hricak H; Barakat RR
J Clin Oncol; 2007 Nov; 25(31):4946-51. PubMed ID: 17971592
[TBL] [Abstract][Full Text] [Related]
17. Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery?
Worley MJ; Guseh SH; Rauh-Hain JA; Williams KA; Muto MG; Feltmate CM; Berkowitz RS; Horowitz NS
Gynecol Oncol; 2013 Apr; 129(1):69-73. PubMed ID: 23375727
[TBL] [Abstract][Full Text] [Related]
18. The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer.
Zivanovic O; Eisenhauer EL; Zhou Q; Iasonos A; Sabbatini P; Sonoda Y; Abu-Rustum NR; Barakat RR; Chi DS
Gynecol Oncol; 2008 Feb; 108(2):287-92. PubMed ID: 17996927
[TBL] [Abstract][Full Text] [Related]
19. Radiological predictors of cytoreductive outcomes in patients with advanced ovarian cancer.
Borley J; Wilhelm-Benartzi C; Yazbek J; Williamson R; Bharwani N; Stewart V; Carson I; Hird E; McIndoe A; Farthing A; Blagden S; Ghaem-Maghami S
BJOG; 2015 May; 122(6):843-849. PubMed ID: 25132394
[TBL] [Abstract][Full Text] [Related]
20. Follow-up study of the correlation between postoperative computed tomographic scan and primary surgeon assessment in patients with advanced ovarian, tubal, or peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease of 1 cm or smaller.
Chi DS; Barlin JN; Ramirez PT; Levenback CF; Mironov S; Sarasohn DM; Iyer RB; Dao F; Hricak H; Barakat RR
Int J Gynecol Cancer; 2010 Apr; 20(3):353-7. PubMed ID: 20375796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
